Nordic Nanovector has raised $60 million to test its CD37-targeting antibody-radionuclide conjugate in combination with rituximab.
Regulus has bulked up its pipeline with two new drug candidates due to start trials next year, as it tries to get lead hep C candidate back on track.
Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.
French digital health player Voluntis snagged a CE mark and FDA clearance for its management device for Type 2 diabetics who are treated with basal insulin.
TiGenix is aiming to net $42.9 million in a Nasdaq IPO, approximately half of which will go toward a U.S. late-phase trial of Crohn's disease candidate…
After a torrid year that has seen multiple deaths in testing, FDA- and self-imposed study halts and its shares tanking, Juno last night held up to the light…
AbbVie has struck five-year cancer research pacts with Johns Hopkins University School of Medicine and Northwestern University's Lurie Cancer Center.
John Jenkins is retiring from the FDA's office for new drugs next year, with Janet Woodcock set to run the office in the interim.
Good Start Genetics is tapping Roche to market its genetic carrier screening technology to obstetricians and general practitioners in the U.S.
A set of researchers at the Fred Hutchinson Cancer Research Center in Seattle who are partially funded by Juno are investigating methods for fine-tuning CAR-T…